Suppr超能文献

通过DNA初免-腺病毒加强免疫有效诱导针对丙型肝炎病毒核心抗原和E2抗原的辅助性T细胞1型CD4 + T细胞应答。

Efficient induction of T helper 1 CD4+ T-cell responses to hepatitis C virus core and E2 by a DNA prime-adenovirus boost.

作者信息

Park Su-Hyung, Yang Se-Hwan, Lee Chang Geun, Youn Jin-Won, Chang Jun, Sung Young Chul

机构信息

National Research Laboratory of DNA Medicine, Division of Molecular and Life Science, Pohang University of Science and Technology, San 31, Hyoja-dong, Nam-gu, Pohang, Kyungbuk 790-784, South Korea.

出版信息

Vaccine. 2003 Nov 7;21(31):4555-64. doi: 10.1016/s0264-410x(03)00499-7.

Abstract

Hepatitis C virus (HCV) is an important causative agent of liver disease, but currently there is no available prophylactic vaccine against HCV infection. Here, we investigated the HCV E2- and core-specific T-cell responses induced by DNA (D) and/or recombinant adenovirus (A) vaccines. In single (D versus A) or double immunizations (D-D versus A-A), the recombinant adenovirus vaccines induced higher levels of IFN-gamma secreting T-cell response and cytotoxic T lymphocytes (CTL) response than the DNA vaccines. However, a heterologous (D-A) regimen elicited the highest level of T helper 1 (Th1) CD4(+) T-cell responses. Furthermore, three E2-specific CTL epitopes were mapped using a peptide pool spanning the E2 protein sequence (a.a. 384-713) in BALB/c mice, and one of these (E2 405-414: SGPSQKIQLV) was shown to be immunodominant. Interestingly, no significant differences were found in the repertoire of E2-specific T-cell responses or in the immunodominance hierarchy of the three epitopes induced by D-D, D-A, A-A, and A-D, indicating that the breadth and hierarchy of T-cell responses is independent of these different vaccination regimens. In conclusion, the heterologous DNA prime-recombinant adenovirus boost regimen described offers an efficient promising strategy for the development of an effective T-cell-based HCV vaccine.

摘要

丙型肝炎病毒(HCV)是肝病的重要致病原,但目前尚无针对HCV感染的预防性疫苗。在此,我们研究了DNA(D)和/或重组腺病毒(A)疫苗诱导的HCV E2和核心特异性T细胞反应。在单次(D与A)或双重免疫(D-D与A-A)中,重组腺病毒疫苗诱导的分泌IFN-γ的T细胞反应和细胞毒性T淋巴细胞(CTL)反应水平高于DNA疫苗。然而,异源(D-A)方案引发了最高水平的辅助性T细胞1(Th1)CD4(+) T细胞反应。此外,在BALB/c小鼠中,使用跨越E2蛋白序列(氨基酸384-713)的肽库定位了三个E2特异性CTL表位,其中一个(E2 405-414:SGPSQKIQLV)显示为免疫显性。有趣的是,在D-D、D-A、A-A和A-D诱导的E2特异性T细胞反应库或三个表位的免疫显性等级中未发现显著差异,这表明T细胞反应的广度和等级与这些不同的疫苗接种方案无关。总之,所描述的异源DNA初免-重组腺病毒加强方案为开发有效的基于T细胞的HCV疫苗提供了一种有效的有前景的策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验